The massive cuts to science, global health, and HIV programs that unfolded in 2025 triggered a crisis with worldwide repercussions. The dissolution of USAID, the shutdown of PEPFAR, and the suspension of thousands of NIH research projects led to an immediate collapse of essential services, from HIV prevention to access to treatment. At the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) held Feb. 22-25, 2026, in Denver, scientists, activists, and health professionals presented data illustrating the scale of the damage and warned of a historic setback in the global HIV response. Read More
Boehringer Ingelheim Ltd. has acquired an exclusive license for a preclinical small-molecule program from Sitryx Therapeutics Ltd. The program offers a novel oral immunometabolic approach to modulating disease-driving immune cells with potential for multiple autoimmune and inflammatory disease indications. Read More
Salt-inducible kinase 2 (SIK2) is a serine/threonine kinase that regulates transcriptional programs in myeloid cells by phosphorylating transcriptional coregulators. In macrophages, SIK2 promotes the expression of proinflammatory cytokines and contributes to the balance between inflammatory and regulatory responses. Researchers from Nimbus Therapeutics LLC presented the preclinical efficacy of NTX-147, a SIK2 selective inhibitor, in ex vivo models of ulcerative colitis (UC). Read More
Gubra A/S has announced the submission in Germany of a clinical trial application (CTA) for a first-in-human study of GUB-UCN2, the company’s lead asset for weight loss. The planned phase I/IIa trial will enroll both healthy volunteers and individuals with obesity, with and without related co-morbidities. GUB-UCN2 is expected to enter clinical development in the first half of this year. Read More
Beam Therapeutics Inc. has added a new program to its liver-targeted genetic disease franchise, BEAM-304, for the treatment of phenylketonuria (PKU). Read More
In a recent study published in Molecular Therapy: Oncology, researchers from the City of Hope National Medical Center and Beckman Research Institute (USA) and collaborators aimed to identify differentially expressed genetic pathways in glioblastoma multiforme (GBM) tumor cells after 48 hours of hypoxia treatment by performing RNA sequencing. Read More
Pivot Therapeutics Inc. has patented RAC-α serine/threonine-protein kinase (AKT1; PKBα) inhibitors potentially useful for the treatment of cancer. Read More
Arcus Biosciences Inc. has reported piperidylurea compounds acting as Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists. Read More
Researchers from Promatix Biosciences Ltd. presented preclinical data on PBS29301A, a first-in-class bispecific ADC developed using Promatix’s proprietary proteomics-based discovery platform. Read More
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has divulged new proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to an EGFR-targeting moiety via a linker. Read More
Prospect Therapeutics Inc. has synthesized new substituted tricyclic derivatives acting as tyrosine-protein kinase JAK1 and non-receptor tyrosine-protein kinase TYK2 inhibitors. Read More
G-protein coupled receptor 68 (GPR68) is an acid-sensing protein receptor that has been implicated in inflammatory bowel disease (IBD) pathogenesis by its modulation of the inflammatory response and fibrosis. Read More
